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Abstract: Migrastatin and isomigrastatin analogues have 
been synthesised in order to contribute to structure-activity 
studies on tumour cell migration inhibitors.  These include 
macrocycles varying in ring size, functionality and alkene 
stereochemistry, as well as glucuronides (macrolides). The 
synthesis work included application of Saegusa-Ito reaction for 
regio- and stereoselective unsaturated macroketone formation, 
diastereoselective Brown allylation to generate 9-
methylmigrastatin analogues and chelation induced 
anomerisation to vary glucuronide configuration.  Compounds 
were tested in vitro against both breast and pancreatic cancer 
cell lines and inhibition of tumour cell migration was observed in 
both wound-healing (scratch) and Boyden chamber assays.  
One unsaturated macroketone showed low affinity for a range of 
secondary drug targets, indicating it is at low risk of displaying 
adverse side effects 
Introduction 
Tumour metastasis is a process where cancer cells detach from 
a primary tumour, migrate and then colonize a distant organ and 
the process leads to mortality for cancer patients.[1] Small 
molecules that interfere with tumour cell migration[2] have 
significant potential as anti-metastatic drugs[3] or as tools[4] for 
the study of tumour cell migration.  Migrastatin 1, is a natural 
product that inhibits tumour cell migration (µM range) in vitro.  
Truncated[5] or simpler analogues of migrastatin, such as 2, 3, 
MGSTA-4 and MGSTA-5 (Figure 1), prepared in Danishefsky’s 
laboratory,[6] have been reported to show orders of magnitude 
higher activity than migrastatin itself in vitro and both 3 and 
MGSTA-5[7] and other compounds[8] have demonstrated 
inhibitory activity in vivo.  We have been engaged in the 
synthesis of migrastatin analogues[9] and recently through 
collaboration with Anderson and Nobis have shown that 
macroketone MGSTA-5 inhibited E-cadherin dynamics in vivo, in 
a manner consistent with increased cell adhesion and reduced 
invasive potential.[10]  It has been reported that the target for 
MGSTA-5 is fascin, which is recognized as being involved in cell 
motility and migration processes and is upregulated in many 
human tumours as well as in several cancer cell lines including 
breast [11], pancreatic.[12] and colon cancer cells.[13] Importantly, 
fascin is also involved in the chemotherapeutic resistance of 
breast.[14] and colon[15] cancer cells. However, whether fascin is 
the target for MGSTA-5 is still debated[16] and there is a belief 
that there may be other unidentified target(s) of migrastatin and 
its analogues.[16] 
 
Figure 1. a) Migrastatin (1) and truncated analogues 2-3 IC50 values (in 
parentheses) in Boyden chamber assay against 4T1 mouse mammary cancer 
cells.[6] b) Modification of migrastatin-core in this paper  
For these reasons the synthesis of analogues of migrastatin, 
including new analogues, continues to be of interest [6, 8, 17] [7, 16b, 
18] [19]. Here we report the the preparation and migrastatin 
analogues shown in Figure 2. The modifications have included 
variation in macrocycle ring size and functionality within the ring 
as well as varying alkene geometry and glucuronidation. 
Included are the syntheses of related isomigrastatin analogues.  
The reasons for synthesis of these various analogues include 
attempts to generate analogues to ultimately contribute to the 
structure-activity relationships and to try to identify more potent 
analogues.  The activity of selected compounds in relevant 
bioassays was subsequently investigated and results of these 
are described.  
 
[a] School of Chemistry, National University of Ireland 
E-mail: paul.v.murphy@nuigalway.ie 
[b] National Centre for Biomedical Engineering Science, National 
University of Ireland, Galway 
[c] Department of Physiological Sciences, Faculty of Veterinary 
Medicine, Warsaw University of Life Science, Warsaw, Poland 
 Supporting information for this article is given via a link at the end of 
the document.((Please delete this text if not appropriate)) 







Results and Discussion 
 
Modification of the macrocycle structure and ring size 
The synthetic work began from intermediate 5, which was 
prepared in ~ two gram quantity using the route recently 
developed in our laboratory.[10]  This intermediate was first used 
to prepare 13-15 membered ring structures based on 
macrolactones, macroketones and macrothiolactones. Firstly, 
the allylic alcohol 5 was coupled to carboxylic acids 6a-c under 
Mitsunobu conditions and the esters formed were then treated 
with the Grubbs-II metathesis catalyst to afford the 
macrolactones 8a-c by ring closing metathesis (RCM). Removal 
of the TBS group using HF.pyridine gave MGSTA-4[6] and its 
new 13 and 15 member analogues MGSTA-1 and MGSTA-8.  
Macroketones, were prepared via conversion of alcohol 6 into 
the allylic bromide 9 and subsequently reacting 9 with β-
ketosulfones 10a-c as previously described[6] to give 11a-c. Ring 
closing metathesis followed by TBS removal afforded MGSTA-
5[6] and new analogues MGSTA-2 and MGSTA-9. Macroketone 
12b was reacted with LHMDS and TMSCl to give an enolate 
which was then oxidized by Saegusa-Ito conditions to afford the 
α,β-unsaturated macroketone 13  which after desilylation gave 
MGSTA-6. Macrothiolactones were prepared via the Mitsunobu 
reaction of thioacids 15a-b with the allylic alcohol 5. Thioacids 
15a and 15b were firstly readily prepared  treating the 
corresponding carboxylic acid with Lawesson’s reagent under 
microwave irradiation.[20] The thioacids 15a-b were not stable to 
silica gel and hence were instead purified by distillation under 
reduced pressure (Kugelrorh, P = 50x10-3 mbar, T = 45 oC, 2h) 
or were used without distillation in the next step. Coupling of 
15a-b to 5 using Mitsunobu conditions, and subsequent RCM 
and TBS group removal afforded macrothiolactones MGSTA-3 
and 7. The compounds MGSTA-1 to 9, were purified using flash 
chromatography (representative mobile phase: petroleum ether-
ethyl acetate, 1:1). The purifty of these macrocyclic agents could 
be increased by their distillation under reduced pressure 
(Kugelrorh, P = 0.05 mbar, T = 90 oC, distillation time from 2h to 
24h). 
 
Scheme 1. Synthesis of migrastatin-core analogues.. Reagents and 
conditions: (a) 6a-c, Ph3P, DIAD, PhCH3, rt; 7a (69%), 7c (76%)  (b) Grubbs-II 
catalyst, PhCH3, reflux, 8a (68%), 12a (99%), 17a (88%), 8c (73%), 12c (60%)  
(c) HF.Py, THF, rt; MGSTA-1 (61%), MGSTA-2 (84%), MGSTA-3 (85%), 
MGSTA-6 (90%), MGSTA-7 (63%), MGSTA-8 (54%), MGSTA-9 (82%) (d) 
CBr4, Ph3P polymer-bound, CH2Cl2; (e) 10a-c, DBU, PhCH3 then 9, rt, 11a 
(51%) 11c (51%), from 9 (f) Na/Hg, MeOH, rt; (g) TMSCl, LHMDS, THF, 0 oC, 
2h; (h) Pd(OAc)2, CH3CN, rt, 2h, 78% from 12b; (i) Lawesson’s reagent, 
CH2Cl2, mw, 100 oC, 10 min; (j) 15a,c, Ph3P, DIAD, PhCH3, rt; 16a (42%), 16b 
(39%) (k) Grubbs-II catalyst, CH2Cl2, mw, 100 oC, 30 min, 17b (49%), . 
 
Synthesis of isomigrastatin analogues  






Isomigrastatin 18, a natural product isolated from Streptomyces 
platensis[21] and a precursor to migrastatin and it is a potent 
inhibitor of tumour cell migration.[17d] In view of this, we have 
used monoprotected diol 19, readily available in 4 steps from 
4,[10] for the preparation of truncated isomigrastatins. Firstly the 
direct exchange of the OH in 19 for Br was attempted, but when 
19 was treated with polymer bound Ph3P and CBr4 in CH2Cl2, 
the methoxy group at C-4 migrated to the C-1 position giving 
allylic bromide 20 (68%), with no trace of the desired compound 
being found. Attempts to form the tosylate or chloride from 19 
led to complex reaction mixtures. On the other hand, when 19 
was coupled with carboxylic acid 6b under Mitsunobu conditions, 
the desired ester 22 was isolated in a 57% yield together with a 
small amount of rearranged compound 21 (14 %). With 22 in 
hand, RCM was next attempted. Unfortunately, reaction of 22 
with the Grubbs-II in toluene only gave a complex mixture (TLC 
evidence) and the desired product was not detected (MS and 
1H-NMR spectroscopic evidence). The TBS group was removed 
from 22 and the secondary alcohol generated then protected as 
the MOM ether 23. In this case, 23 readily cyclized using 
Grubb’s 2nd to afford macrocycle 24 (Scheme 2) as previously 
described.[22] A mechanistic proposal for formation of 20 and 21 
is suggested in Scheme 2 B. 
 
Scheme 2. A) Reagent and conditions: (a) CBr4, Ph3P polymer-bound, CH2Cl2, 
rt; 1h, 68%; (b) 6b, Ph3P, DIAD, PhCH3, rt; 57%; (c) TBAF, THF, rt, 3 days, 
60%; (d) MOMCl, CH2Cl2, Hunig’s base, 0 oC to rt, 18h, 60%; (e) Grubbs-II 
catalyst, PhCH3, reflux; 31% 1IC50 values using  4T1 mouse mammary 
adenocarcinoma cells. 2IC50 values using MDA-MB-231 human breast 
adenocarcinoma cells[17d]; B) Proposed mechanism for formation of 20 and 21 
under Mitsunobu and Appel conditions. 
 
Synthesis of 9-methylmacrolactone analogues of 
migrastatin and isomigrastatin. 
 
Brown allylation was used as the key step to generate an 
analogue bearing a methyl group instead of methoxy group at C-
9.  Thus Brown allylation[23] of 25 (Scheme 3) with cis-butene 
and β-methoxydiisopinocampheylborane installed two 
contiguous stereocenters  with subsequent removal of the 
benzoate group enabling diol 26 to be isolated in moderate yield; 
the relative configuration was determined by obtaining an X-ray 
crystal structure determination for 26.  Diol 26 was then 
protected as its di-O-TBS ether and subsequent treatment with 
10% TsOH in MeOH removed the TBS group from the primary 
position to give the alcohol 27.  This alcohol 27 was oxidized 
with the Dess-Martin periodinane and the aldehyde obtained 
was then treated with the Ando phosphonate[17b, 17k, 24] 35 to give 
28. Reduction of the ester group in 28 using DIBAL-H gave a 
primary alcohol and its subsequent Mitsunobu reaction gave 29. 
However, RCM of 29, under several conditions and reaction 
time, only gave complex reaction mixtures (TLC) with no trace of 
the desired product. Alcohol 32 was prepared with a view to 
resolving this problem and for application in isomigrastatin 
analogue synthesis.  Since the presence of the TBS group was 
problematic in the attempted RCM with compound 22, the 
secondary alcohol was protected as its MOM ether. 
Regioselective protection of the primary alcohol in 26 with a 
TBDPS group gave 30 and subsequent protection of its 
secondary alcohol as MOM ether afforded the orthogonally 
protected alkene 31 which gave 32 after TBDPS removal. 
Scheme 3. Synthesis of methyl migrastatin-core analogues.. Reagents and 
conditions: (a) i. cis-Butene, n-BuLi, THF, 45 min, -20oC; ii. (+)-Ipc2BOMe, 30 
min, -78oC; iii. BF3.Et2O, then 25, 28h; iv. NaOH 1N, H2O2 30%, 16h; (b) 
K2CO3, MeOH, RT, 24h, 32% from 25; (c) TBSOTf, DCM, DIPEA, 0oC, 5h; (d) 
p-TSA, MeOH, 3h 0oC, 62% from 26; (e) DMP, CH2Cl2, RT, 18h, 88%; (f) 35, 
THF, NaH, 0oC, 1h, then aldehyde obtained from oxidation of 27, -78oC to RT, 
18h, 85%; (g) DIBAL, CH2Cl2, -78oC, 10 min. 63%; (h) Ph3P, DIAD, 6-
heptenoic acid, RT, 2h, 81%; (i) Grubbs-II catalyst, PhCH3, reflux; (j) TBDPSCl, 
imidazole, CH2Cl2, RT, 62%; (k) MOMCl, DIPEA, CH2Cl2, RT, 48h, 89%; (l) 
TBAF 1M, THF, RT, 18h, 98%; (m) Ph3P, DIAD, 6-heptenoic acid, RT, 4h, 
88%; (n) Grubbs-II catalyst, PhCH3, 1h, heat at reflux, 33% MGSTA-12 & 31% 
MGSTA-11; (o) TMSBr, CH2Cl2, -20oC, 2h 77% (MGSTA-13), 74% (MGSTA-
14); (p) DMP, CH2Cl2, pyridine, RT, 4h, 70%; (q) 35, THF, NaH,0oC, 1h, then 






aldehyde obtained from the oxidation of 32, -78oC to RT, 15h, 73%; (r) DIBAL, 
CH2Cl2, -78oC, 15 min. 76%; (s) Ph3P, DIAD, 6-heptenoic acid, RT, 3h, 78%; 
(t) Grubbs-II catalyst, PhCH3, benzoquinone, 80oC, 5h, 13%; (u) TMSBr, 
CH2Cl2, -20oC, 3h, 60%.  
 
The Mitsunobu reaction of 32 gave MGSTA-10. Ring-closing 
metathesis of MGSTA-10 afforded cis and trans alkene 
containing macrocycles MGSTA-11 and MGSTA-12 in a 1:0.85 
ratio. The MOM protecting group was removed from both 
intermediates using TMSBr to give truncated isomigrastatin 
analogues MGSTA-13 and MGSTA-14. For the synthesis of 
migrastatin-core analogue MGSTA-15 bearing the methyl group 
at C-9, the primary alcohol 32 was oxidized using the Dess-
Martin periodinane, and then treated with the Ando 
phosphonate[17b, 17k, 24] 35 giving the trisubstituted alkene 33, with 
the Z configuration. The configuration of the newly formed 
double bond was supported by NOE spectroscopic experiments, 
where NOEs were observed for 33 as indicated in Scheme 3. 
The reduction of 33 with DIBALH and subsequent esterification 
using Mitsunobu conditions gave the RCM precursor to S6.  As 
for 29, the RCM reaction of this precursor was unsuccessful and 
macrocyclic product could not be detected under several 
reaction conditions. Fortunately, addition of 1,4-benzoquinone[25] 
to the reaction mixture led to formation of desired 34 in modest 
yield, which after deprotection afforded the 9-methyl-
macrolactone MGSTA-15.  
Synthesis of migrastatin glucuronides 
Glucuronides are an important class of phase 2 metabolites and 
glucuronidation in vivo of small molecules usually leads to 
compounds with higher water solubility, which are more easily 
excreted through the kidney.[26] Glucuronide metabolites are 
often biologically inactive but in some cases can display 
interesting bioactivity.[27] [28] The 6-O-glucuronide of morphine 
(M6G) displays full agonist properties at the µ1 opioid receptor 
and appears to be more potent than morphine itself with fewer 
side effects.[26, 29] In addition, the glucuronide of ezetimibe, a 
selective inhibitor of cholesterol absorption, is more active than 
ezetimibe itself.[26] [30] The biological activity of thiocolchicoside, a 
myorelaxant used for painful muscle contraction, has to be 
attributed to the presence of the 3-O-glucuronidated aglycone.[26] 
A glucuronide can be hydrolyzed through an enzymatic or non-
enzymatic reaction to give the active aglycon[27] In this latter 
context glucuronidation has been used as for the preparation of 
SN-38 and taxol prodrugs.[27, 31] The strategy relies on the fact 
that β-glucuronidase is generally overexpressed in tumour 
tissues. In view of these interesting properties of glucuronides 
and of the possibility that in vivo generation of glucuronides can 
occur we decided to prepare the glucuronide of MGSTA-5.   
Thus, MGSTA-5, which had been prepared on 100 mg scale, 
was coupled with trichloroacetimidate 36[32] using TMSOTf 
affording exclusively the protected β-glucuronide 37. 
Simultaneous removal of benzoate protective groups and 
hydrolysis of the methyl ester using aqueous NaOH gave the 
macroketone β-glucuronide MGSTA-16. In order to obtain the α-
anomer of this glucuronide we applied the chelation induced 
anomerization[33], which has been of interest in our laboratory[33d] 
for the synthesis of the α-glucuronide.  Thus, glucuronide 37 was 
treated with TiCl4 in CDCl3 at 4 oC giving the α-glucuronide 38 as 
the only product.  Deprotection and ester hydrolysis gave 
MGSTA-17.  
 
Synthesis of glutarimide containing analogues of 
migrastatin where alkene geometry is varied. 
 
The preparation of MGSTA-18 and MGSTA-19, containing the 
glutarimide side-chain, where olefin geometry is modified in the 
macrocyclic core was included in the synthetic study. Thus, 
diene precursors were prepared from freshly prepared aldehyde 
39 (Scheme 5) using Wittig reagent 40 to give the E-alkene 41 
with high stereoselectivity (E:Z = 25:1); this reaction provided the 
isomer which would enable preparation of migrastatin analogues 
with an E-alkene at C-3 in the macrocycle. The subsequent 
steps were similar to those used by Danishefsky and co-
workers[6, 17h] for their preparation of migrastatin.  Thus, the 
reduction of the ester with DIBAL-H gave the corresponding 
allylic alcohol which was subsequently oxidized using the Dess-
Martin reagent and the aldehyde generated was reacted with 
propionyl oxazolidinone 42 in the presence of MgCl2, 
triethylamine, and TMSCl to afford, after treatment with TFA, the 
desired anti-aldol product 43. Protection of the hydroxy group as 
a TES ether, and reductive removal of the auxiliary gave primary 
alcohol 44 in good yield (Scheme 5). The glutarimide aldehyde 
47 needed for the introduction of the glutarimide chain was 
prepared from 45 via thioester 46 (Scheme 5).[34] 
 
  
Scheme 4. Reagents and conditions: (a) 36 TMSOTf, MS (AW300), 
CH2Cl2, -78 oC, 5h, 60%; (b) TiCl4, CDCl3, 4 oC, 69%; (c) NaOH aq., MeOH, rt, 
18h, MGSTA-17 (61%), MGSTA-16 (73%). 
 
With 44 in hand the preparation of 51 was next completed.  
Hence Dess-Martin oxidation of 44 gave the corresponding 
aldehyde which was reacted with the anion generated by 
reaction of dimethyl methylphosphonate with butyl lithium to give 
an alcohol intermediate. Oxidation of this alcohol afforded 
phosphonate 48. Then glutarimide aldehyde 47 was treated with 
48 using the Masamune-Roush variant of the Horner-
Wadsworth-Emmons reaction, giving the corresponding E-enone 
which was reduced with the Stryker reagent 50 and subsequent 
selective cleavage of TES protecting group gave alcohol 49 
(Scheme 6). The synthesis of stereoisomers of migrastatin was 
possible with 49 in hand, as it had a trisubstituted alkene with 






the E-configuration (Scheme 6). Thus the modified Yamaguchi 
acylation from 2,6-heptadienoic acid gave 51. However, the 
subsequent RCM reaction, attempted using both the Grubbs-II 
and Hoveyda-Grubbs-II catalysts, did not give rise to a ring 
closed product. The coupling of 49 with 6-heptenoyl chloride, 
which gave 52 was carried out. Substrate 52 does not contain 
the unsaturated ester and in this case the RCM reaction 
succeeded and gave the ring closed product as a mixture of E- 
and Z-stereoisomers (2:1), which were difficult to separate.  
Removal of the TBS group from the mixture was effectively 
achieved using HF-pyridine to give both 53a and 53b. The 
presence of both Z:E isomers in the mixture was deduced by 
alkene proton signals in the 1H-NMR spectrum of the mixture of 
53a and 53b with coupling constants J = 10.7 Hz (Z) and J = 
15.2 Hz (E). 
Scheme 5. Reagents and conditions: (a) 40, PhCH3, reflux, 22h, 96%; (b) 
DIBAL, CH2Cl2, - 78 oC, 2h, 84%; (c) Dess-Martin, CH2Cl2, pyridine, 18h, 92%; 
(d) 42, MgCl2, Et3N, TMSCl, rt, 48h then TFA, MeOH; (e) TESCl, CH2Cl2, 
imidazole, rt, 12h, 88% over two steps; (f) LiBH4, MeOH, THF, rt, 1h, 86%; (g) 
N-methylimidazole, TsCl, MeCN then 1-dodecanthiol, 70 min. 0oC, 80%; (h) 
Pd/C 10%, Et3Si, acetone, RT, 1h, 91%. 
 
Encouraged that the presence of the E-alkene in 52 did not 
totally preclude macrocycle formation by RCM, we revised the 
approach to MGSTA-18 and MGSTA-19.  Danishefsky and his 
co-workers, in their total synthesis of isomigrastatin,[35] reported 
that RCM gave the 12-membered ring only when the alkene 
group adjacent to the carbonyl group was absent. They used an 
α-phenylselenide derivative and introduced the alkene adjacent 
to the carbonyl group after RCM. In order to obtain MGSTA-18 
and MGSTA-19 the selenium containing acid 55 was therefore 
first prepared from commercially available 54 in two steps. 
Yamaguchi acylation of 49 with racemic 55 and subsequent 
removal of the TBS group provided a mixture of 
diastereoisomers 56. The RCM from 56 using the Grubbs-II 
reagent gave a 1:2 mixture of E-isomer 57a (not shown) and the 
Z-isomer 57b. The polarity of 57a and 57b was similar on TLC, 
but it was possible to separate small amounts of 57a and 57b 
through repeated chromatographic purification steps. However, 
despite repeated chromatography it was not possible to obtain 
these compounds with high purity at the scale at which the 
reaction was carried out. Thus the oxidative deselenation of the 
Z-isomer 57b was carried out with the material obtained and this 
gave the E-isomer MGSTA-19 in 42% yield, along with 23% of 
the Z-isomer MGSTA-18 (Scheme 7). 
 
Scheme 6. Reagents and conditions: (a) Dess-Martin, CH2Cl2, rt, 1.5h,(b) 
dimethyl methylphosphonate, BuLi, -78oC to 0oC, 15 min.; (c) Dess-Martin, 
CH2Cl2, rt, 1h, 69% over three steps; (d) 47, LiCl, DBU, CH3CN, 1h, rt, 94%; 
(e) 50, PhCH3, rt, 89%. (f) AcOH, THF, H2O, rt, 3h, 97%; (g) (E)-2,6-
heptadienoic acid, 2,4,6-thrichlorobenzoyl chloride, DIPEA, pyridine, PhCH3, 
88%; (h) 6-heptenoyl chloride, DMAP, CH2Cl2, RT, 75%; (i) Grubbs-II catalyst, 
PhCH3, 1h, reflux, 70%; (j) HF.Py, THF, RT, 75%. 
 
Scheme 7. Reagents and conditions: (a) BuLi, iPr2NH, Ph2Se2, THF; (b) 
LiOH, THF/H2O/MeOH, 86%; (c) 55, 2,4,6-trichlorobenzoyl chloride, DIPEA, 
PhCH3, RT, 3h then 49, toluene, pyridine, RT, 4 days, 92%; (d) HF.pyridine, 
pyridine, RT, 24h, 61%; (e) Grubbs-II catalyst, PhCH3, reflux; 5 min, 78% (f) 
mCPBA, CH2Cl2, -78oC, 30 min. then DIPEA, RT, 2h, MGSTA-18 (23%), 
MGSTA-19 (42%).  
 
The structural assignment for MGSTA-19 was supported by a 
typical α,β-unsaturated ester proton signal (δ 6.83) with J value 
typical of a Z-alkene (16.0 Hz) whereas MGSTA-18 had a signal 
at δ 6.23 and J value typical of E-alkene (11.1 Hz).   
 






Biological evaluation of migrastatin-core analogues 
 
With a variety of congeners now prepared, biological studies 
were next carried out with the capacity of compounds to inhibit 
tumor cell migration investigated using both wound healing and 
trans-well assays.  Firstly, in order to eliminate the possibility 
that any decrease of migration was caused by an inhibition of 
cell proliferation or toxicity, rather than an interaction with the 
cell motility machinery, the effect of newly synthesized 
migrastatin-core analogues on three breast (MCF7, MCF7-Dox, 
MDA-MB361) and one pancreatic cancer (HPAC) cell lines were 
evaluated using the MTT assay.  The newly synthesized 
analogues did not cause any toxicity or arrest of proliferation at 
the tested concentrations (1, 10 & 100 μM) (see supporting 
information provided).  Therefore wound healing assays were 
next carried out to address the effect on cell migration following 
exposure to compounds. The migrastatin analogues when given 
at the concentration of 10 µM strongly inhibited migration of the 
low-invasive MCF7[36] and doxorubicin resistant MCF7-Dox 
breast cancer cells, with average scratch closure of 14.6% and 
14.9% respectively. Interestingly, treatment of MDA-MB361 
breast cancer cells with migrastatin analogues resulted in the 
inhibition of cell migration with an average scratch closure of 
42.0%. MDA-MB361 are known to have poor cell-cell 
adhesion.[36] As a result, some migrastatin analogues were 
tested on the MDA-MB-231 cell line, that display a more invasive 






phenotype, [36] and with this in vitro model, the average scratch 
closure was 63.3%. When the migrastatin analogues where 
tested on the pancreatic cancer cell line, HPAC, we noted an 
average of scratch closure of 33.5% (see supporting 
information).  
Next a selected number of the compounds tumour cell 
migration inhibitory activity was evaluated using the Boyden 
chamber assay as this is considered a superior model with 
which to conduct cell migration studies.[1] Eight of the 
compounds were selected based on considering macrocycle 
ring size and other structural features: compounds MGSTA-13 
and MGSTA-14 were selected because of their relationship to 
the isomigrastatin macrocyclic core; MGSTA-9 contains an extra 
carbon in the macrocyclic ring compared to migrastatin; 
MGSTA-6 possesses an α,β-unsaturated carbonyl group that is 
present in migrastatin; MGSTA-15 is the direct analogue of 
MGSTA-4 with a methyl group instead of a methoxy in the 9 
position; MGSTA-16 and 17 are the glucuronides and MGSTA-5 
(Danishesky’s macroketone), was selected for use as the 
internal control.  As shown in Figure 2 and 3, the selected 
compounds, inhibit cell migration in the less invasive MCF7 cells 
in the nanomolar range. The only exception was MGSTA-6 
which inhibited cell migration with considerably lower potency 
(IC50 > 1µM) when compared with the macroketone MGSTA-5 
(IC50 = 13 nM). The glucuronides were found to be less potent 
than the macroketone against this cell type with the β-
glucuronide more potent than its α-anomer.   MGSTA-5,6 and 14 
were tested using the more invasive MDA-MB361 cell line. 
Interestingly, MGSTA-6 (IC50 = 410 nM) was 2.4 fold more 
potent than MGSTA-5 (IC50 = 974 nM) in this particular cell line, 
contrasting with the result for the MCF7 cells.  In addition, the 
isomigrastatin-core analogue MGSTA-14 strongly inhibited cell 
migration of MDA-MB361 cells (IC50 = 301 nM). MGSTA-
5,6,9,15,16 and 17 all strongly inhibited cell migration in HPAC 
cells, however, the curve dose response was very wide and the 
IC50 could not be extrapolated. 
 
 
Figure 3. The effect of selected migrastatin analogues on human breast 
cancer cell lines MCF7 and MDA-MB36 assessed with Boyden chamber assay. 
 
Thus, MGSTA-6 showed good cell migration inhibition in highly 
metastatic MDA-MB361 but not in less invasive MCF7 cells. This 
apparent paradox could be related with cytoskeleton proteins 
targeted by migrastatin analogues [9, 19] and with differents 
molecular changes occurring during the complex event of 
metastasis in invasive and non invasive cells. In a previous 
paper we showed that MGSTA-6 inhibited the formation and 
elongation of filopodia by interfering with fascin1-dependent 
cross-linking of actin filaments and subsequently leads to 
inhibition of stress fibres formation.[9] Importance of these 
cytoskeleton rearangements in cancer invasion indicates a 
correlation between high fascin expression and poor prognosis 
in human carcinomas.[37] Stress fibre formation is the last and 
crucial step of complex changes occuring in cytoskeleton of 
invasive cancer cell before its movement and it could tentatively 
explain the more pronounced biological activity of MGSTA-6 in 
MDA-MB361 cells (figure 2). 
 
In vitro pharmacological profile of MGSTA-6 
The pharmacological profile of a biologically active small 
molecule can be classified into primary (interaction with the 
intendent target) and secondary (interactions with differents 
targets). Interaction with secondary targets can lead to adverse 
drug reaction (ADRs). From the drug discovery point of view, it is 
extremely important to identify the potential side effects as early 
as possible. Recently,[38] it has been suggested that drug 
candidates should be screened against a variety of targets 
(receptors, ion channels, enzymes and transporters).  
Compounds that interact with several of the above mentioned 
targets, are more prone to induce ADRs. Unsaturated 
macroketone MGSTA-6 strongly inhibits cell migration in MDA-
MB361 and HPAC cells (see above) and was earlier shown to 
interfere with the fascin1-dependent cross-linking of actin 
filaments leading to inhibition of stress fibers formation in canine 
mammary cancer cells.[9]  This agent was therefore selected 
from the panel of agents for screening against 55 targets 
(receptors, ion channels and transporters) known to be linked to 
ADRs. At the concentration of 10 µM, MGSTA-6 only showed 
weak inhibition of two targets: adenosine receptor A2A (27%) and 
prostanoid EP4 receptor (39%). It has been suggested[38] that 
compounds with a promiscuity index (percentage of targets 
giving more than 50% inhibition at 10 μM in a set of at least 50 
targets) of more than 20% should be considered promiscuous 
and this has been linked to market withdrawal and clinical trial 
failure. Unsaturated macroketone MGSTA-6, with a promiscuity 
index between 0-5%, is a possible candidate as a tumour cell 
migration inhibitor with potentially low side effects. However, the 
pharmacological panel in this study does not include enzymes 
and further investigations would be necessary in order to confirm 
the selectivity of MGSTA-6 (Table S1).  
Conclusions 
The stereoselective synthesis of intermediates based on Brown 
allylation and alkoxyallylation has enabled the preparation of a 
series of migrastatin and isomigrastatin analogues.  Chelation 
induced anomerisation is compatible with the various 
functionality found in the migrastatin macroketone skeleton and 
could be exploited to give macroketone glycosides for biological 
study.  Compounds showed inhibitory activity when tested 
against breast and pancreatic cancer cell lines (MCF-7, MCF7-
Dox, MDA-MB631, MDA-MB261, HPAC) using the wound 
healing assay and Boyden chamber assay  (nM range). One 
inhibitor (MGSTA-6) has low activity against a variety of 
receptors, ion channels and transporters, which indicates that it, 






and possibly other migrastatin analogues, may have potential to 
inhibit tumour metastasis without adverse drug reactions.   
Experimental Section 
 
General: NMR spectra were recorded on a 500 MHz spectrometer at 30 
oC. Chemical shifts are reported relative to internal Me4Si inCDCl3 (δ=0.0 
ppm) for 1H and CDCl3 (δ =77.16 ppm) for 13C at 30 oC, unless otherwise 
stated. 13C signals were assigned with the aid of HSQC. Coupling 
constants are reported in Hertz. High-resolution mass spectra were 
measured by using an LC time-of-flight mass spectrometer and were 
measured in positive and/or negative mode as indicated. TLC was 
performed on aluminium sheets pre-coated with Silica Gel 60 (HF254, 
Merck Millipore) and spots were visualised by charring with vanillin 
solutions. Chromatography was carried out by using silica gel 60 (0.040–
0.630 mm, E. Merck). Dichloromethane, tetrahydrofuran, MeOH and 
toluene were used as obtained from a PureSolv solvent purification 
system. Petroleum ether is the fraction with b.p. = 40–60 oC. 
General procedure for TBS deprotection. To a stirred solution of TBS 
protected macrocycle in THF (24 mM), HF•pyridine 70% (250 eq) was 
added at RT. The resulting solution was stirred at RT for 18 h. After the 
careful addition of MeOTMS (350 eq) the mixture was stirred for an 
additional 30 min and then the solvent was removed under reduced 
pressure and the residue was purified by flash chromatography (FC). 
(6E,8S,9S,10R,11Z)-9-hydroxy-8-methoxy-10,12-
dimethyloxacyclotrideca-6,11-dien-2-one (MGSTA-1). Purification by 
FC (PE/EtOAc 10:1) afforded MGSTA-1 (15.1 mg, 61%) as a white solid; 
[α]
D 
-13.0° (c 0.03, CHCl3); 1H NMR (CDCl3, 500 MHz): δ 5.65- 5.61 (m, 
1H, H-11) 5.62–5.57 (dd, 1H, J6,7trans = 15.5, J5,6 = 7.5 Hz, H-6), 5.26 (ddt, 
1H, J7,8 = 6.2, J =1.4 Hz, H-7), 5.13 (dd, 1H, J13,13’ = 12.1, JMe,13 = 1.2 Hz, 
H-13), 3.82 (d, 1H, H-13’), 3.41–3.34 (m, 1H, H-8), 3.31 – 3.27 (m, 4H, 
OCH3, H-9), 2.42–2.28 (m, 3H, CH2, H-10), 2.27–2.12 (m, 2H, CH2), 
2.05–1.94 (m, 1H, CH2), 1.82 (d, 3H, CH3 at C-12), 1.77–1.68 (m, 1H, 
CH2), 0.95 (d, 3H, J10,10Me = 6.8 Hz, CH3 at C-10); 13C NMR (CDCl3, 125 
MHz): δ 173.4 (C-2), 136.4 (C-11), 132.9 (C-6), 129.3 (C-7), 128.5 (C-12), 
82.7 (C-8), 77.6 (C-9), 63.3 (C-13), 56.8 (OCH3), 32.9 (C-10), 32.0 (CH2), 
31.7 (CH2), 24.0 (CH3  at C-12), 21.8 (CH2), 13.0 (CH3  at C-10); HRMS-
ESI: calcd for C15H24O4Na: 291.1572; Found: 291.1584. 
(4Z,6R,7S,8S,9E)-7-hydroxy-8-methoxy-4,6-dimethylcyclotrideca-4,9-
dienone (MGSTA-2). Purification by FC (PE/EtOAc 10:1) afforded 
MGSTA-2 (11.8 mg, 84%) as a yellow syrup; [α]
D 
87.4 (c 1.64, CHCl
3
); 1H 
NMR(CDCl3, 500 MHz): δ 5.62 (ddd, 1H, J9,10trans = 15.0, J10,11 = 8.5, 
J10,11’ = 5.9 Hz, H-10), 5.30 (d, 1H, J5,6 = 10 Hz, H-5), 5.22 (ddt, 1H, J8,9 = 
7.6, J = 1.3 Hz, H-9), 3.37-3.34 (m, 1H, H-8), 3.31-3.29 (m, 4H, H-7 and 
OCH3), 2.82 (s, 1H, OH), 2.64-2.59 (m, 1H, CH2), 2.51–2.45 (m, 2H, 
CH2), 2.43–2.25 (m, 4H, H-6, CH2), 2.10–2.03 (m, 1H, CH2), 1.91–1.81 
(m, 2H, CH2), 1.76–1.70 (m, 1H, CH2), 1.70 (d, 3H, J = 1.3 Hz, CH3 at C-
4), 0.95 (d, 3H, J6,Me = 6.9 Hz, CH3 at C-6); 13C NMR (125 MHz, CDCl3) δ 
210.7 (C-1), 135.7 (C-10), 133.9 (Cq), 130.7 (C-5), 129.5 (C-9), 83.9 (C-
8), 77.8 (C-7), 56.4 (OCH3), 42.5 (CH2), 40.2 (CH2), 32.9 (C-6), 31.9 
(CH2), 26.3 (CH2), 23.6 (CH3), 21.5 (CH2), 13.9 (CH3). HRMS-ESI: calcd 
for C16H26O3Na: 289.1780; Found: 289.1772.  
(6E,8S,9S,10R,11Z)-9-hydroxy-8-methoxy-10,12-
dimethylthiacyclotrideca-6,11-dien-2-one (MGSTA-3). Purification by 
FC (PE/EtOAc 15:1) afforded MGSTA-3 (5.0 mg, 85%) as a yellow 
syrup; [α]
D 
1.6 (c 0.46, CHCl
3
); 1H NMR(CDCl3, 500 MHz): δ 5.65–5.48 
(m, 2H, H-6,10), 5.15–5.05 (dd, 1H, J6,7trans = 15.4, J7,9 = 7.7 Hz, H-7), 
4.21 (d, 1H, J = 13.4, H-13), 3.33–3.27 (m, 2H, H-7,8), 3.26 (s, 3H, 
OCH3), 2.84 (s, 1H, OH), 2.78 (d, 1H, H-13’), 2.66 (ddd, 1H, J = 16.7, 7.0, 
2.0 Hz, H-3), 2.57–2.51 (m, 1H, H-3’), 2.51–2.42 (m, 1H, H-5), 2.22 (m, 
1H, H-4), 2.12 (m, 1H, H-10), 2.01–1.92 (m, 1H, H-5’), 1.76 – 1.74 (s, 3H, 
Me at C-12), 1.69–1.62 (m, 1H, H-4’), 0.97 (d, 3H, J10,Me = 6.8, Hz, Me at 
C-10).13C NMR (125 MHz, CDCl3): δ 198.0 (C-2), 136.8 (C-6), 133.9 (C-
10), 130.1 (C-11), 128.8 (C-7), 83.1 (C-8 or C-9), 75.0 (C-8 or C-9), 56.3 
(OCH3), 43.7 (C-3), 34.3 (C-5), 32.5 (C-10), 28.9 (C-13), 25.3 (CH3 at C-
12), 22.7 (C-4), 12.6 (CH3 at C-10). HRMS-ESI: calcd for C15H23O3S: 
283.1368; Found: 283.1375. 
(2E,6E,8S,9S,10R,11Z)-9-((tert-butyldimethylsilyl)oxy)-8-methoxy-
10,12-dimethylcyclotetradeca-2,6,11-trien-1-one (13). 
To stirred 12b (26.7 mg; 0.068 mmol) in THF (0.5 mL) at 0oC, TMSCl (26 
µL; 0.203 mmol) and LHMDS (203 µL; 0.203 mmol, 1M in THF) were 
added dropwise. The resulting solution was stirred for 2h at 0oC, 
quenched with NH4Cl and extracted with EtOAc. The organic layers were 
dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure. The residue was dissolved in CH3CN (0.5 mL) and Pd(OAc)2 
(18 mg; 0.082 mmol) was added. The mixture was stirred for 3h and then 
diluted with NaHCO and extracted with CH2Cl2. The organic layers were 
dried over Na2SO4, filtered and the solvent was removed under reduced 
pressure. Purification by FC (PE/EtOAc 20:1) afforded 14 (17 mg: 64%) 
as a yellow syrup; [α]
D 
42.9° (c 1.2, CHCl
3
); 1H NMR(CDCl3, 500 MHz): δ 
6.74 (dt, 1H, J2,3 = 16.2, J3,4 = 7.0 Hz, H-3), 5.93 (d, 1H H-2), 5.64 (ddd, 
1H, J6,7 = 15.4, J = 8.9, J = 4.7 Hz, H-6), 5.37–5.14 (m, 2H, H-7,11), 
3.45–3.27 (m, 2H, H-8,9), 3.21 (s, 3H, OCH3), 2.70–2.31 (m, 7H, H-
10,CH2), 2.31–2.20 (m, 1H, CH2), 2.05 (m, 1H, CH2), 1.69 (d, 3H, J = 1.5 
Hz, Me at C-12), 0.90 (s, 9H, C(CH3)3), 0.87 (d, 3H, J = 6.6 Hz, Me at C-
10), 0.04 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3); 13C NMR (125 MHz, 
CDCl3): δ 201.5 (C-1), 148.2 (C-3), 132.8 (C-6), 132.0, 132.0, 131.7, 
131.4, 85.2 (C-8 or C-9), 79.0  (C-8 or C-9), 56.4 (OCH3), 38.4 (CH2), 
34.5 (C-10), 32.4 (CH2), 31.6 (CH2), 30.7 (CH2), 26.3 (C(CH3)3), 23.0 (Me 
at C-12), 18.8 (C(CH3)3), 12.7(Me at C-10), -3.7 (SiCH3), -4.9 (SiCH3); 
HRMS-ESI: calcd for C23H39O3Si: 391.2668; Found: 391.2678. 
(2E,6E,8S,9S,10R,11Z)-9-hydroxy-8-methoxy-10,12-
dimethylcyclotetradeca-2,6,11-trienone (MGSTA-6). Purification by FC 
(PE/EtOAc 5:1) afforded MGSTA-6 (7.6 mg, 90%) as a yellow syrup; [α]
D 
92.2° (c 0.6, CHCl
3
); 1H NMR(CDCl3, 500 MHz): δ 6.73 (dt, 1H, J2,3 =16.4, 
J3,4 = 7.1 Hz, H-3), 5.93 (d, 1H, H-2), 5.69 (ddd, 1H, J6,7 = 15.4, J = 9.4, J 
= 4.4 Hz, H-6), 5.37 (d, 1H, J10,.11 = 9.9 Hz, H-11), 5.24 (ddd, 1H, J7,8 = 
8.4, J = 1.4 Hz, H-7), 3.44 (appt, 1H, J7,8 = J8,9 = 8.9 Hz, H-8), 3.34 (dd, 
1H, J = 1.3 Hz, H-9), 3.31 (s, 3H, OCH3), 2.70 (s, 1H, OH), 2.64 (m, 1H, 
CH2), 2.57–2.46 (m, 4H, H-10, CH2), 2.42–2.22 (m, 3H, CH2), 2.14 (m, 
1H, CH2), 1.72 (d, 3H, J = 1.4 Hz, Me at C-12), 0.92 (d, 3H, J = 6.8 Hz, 
Me at C-10); 13C NMR (125 MHz, CDCl3): δ 201.3 (C-1), 147.8 (C-3), 
134.9 (C-6), 132.9 (C-12), 131.7 (C-2), 130.9 (C-11), 130.5 (C-7), 84.1 
(C-8), 77.2 (C-9), 56.6 (OCH3), 38.4 (CH2), 32.7 (C-10), 32.3 (CH2), 31.3 
(CH2), 30.6 (CH2), 22.9 (Me at C-12), 12.6 (Me at C-10). HRMS-ESI: 
calcd for C17H25O3: 277.1804; Found: 277.1801. 
(7E,9S,10S,11R,12Z)-10-hydroxy-9-methoxy-11,13-
dimethylthiacyclotetradeca-7,12-dien-2-one (MGSTA-7). Purification 
by FC (hexane/EtOAc 15:1) afforded MGSTA-7 (12.8 mg, 63%) as a 
yellow syrup; [α]
D 
93.2 (c 0.07, CHCl
3
);1H NMR(CDCl3, 500 MHz): δ 
5.80–5.70 (m, 1H, H-7), 5.58 (d, 1H, J11,12 = 9.6 Hz, H-12), 5.28–5.20 
(ddt, 1H, J7,8 = 15.8, J8,9 = 7.3, J = 1.4 Hz, H-8), 3.72 (d, 1H, J14,14’ = 12.4 
Hz, H-14), 3.43 (dd, 1H, J9,10 = 9.0 Hz, H-9), 3.35 (dd, 1H, J10,OH = 1.6 Hz, 
H-10), 3.30 (s, 3H, OMe), 3.18 (d, 1H, H-14’), 2.80 (bs, 1H, OH), 2.61 (m, 
1H), 2.49–2.37 (m, 2H, H-11 and CH2), 2.22 (m, 1H), 2.02 (m, 1H), 1.77 
(d, 3H, J = 1.4 Hz, Me at C-13), 1.75–1.59 (m, 3H), 1.45–1.35 (m, 1H), 






0.95 (d, 3H, J = 6.9 Hz, Me at C-11); 13C NMR(CDCl3, 125 MHz): δ 200.9 
(C-2), 135.0 (C-7), 134.2 (C-12), 128.4 (C-13), 127.8 (C-8), 83.8 (C-9), 
76.6 (C-10), 56.6 (OMe), 43.5 (CH2), 32.9 (C-11), 31.1 (C-14), 29.6 (CH2), 
27.4 (CH2), 25.6 (CH2), 25.1 (Me at C-13), 12.8 (Me at C-11); HRMS-ESI: 
calcd for C16H26O3NaS: 321.1500; Found: 321.1496.   
(8E,10S,11S,12R,13Z)-11-hydroxy-10-methoxy-12,14-
dimethyloxacyclopentadeca-8,13-dien-2-one (MGSTA-8). Purification 
by FC (PE/EtOAc 10:15:1) afforded MGSTA-8 (28.7 mg, 54%) as a 
white syrup; [α]
D 
72° (c 1.7, CHCl
3
); 1H NMR(CDCl3, 500 MHz): δ 5.79 
(dq, 1H, J12,13 = 9.4, J13,Me = 1.6 Hz, H-13), 5.64 (ddd, 1H, J8,9 =15.3, J8,7 
= 8.9, J8,7’ = 5.2 Hz, H-8), 5.16 (dd, 1H, J9,10 = 8.0 Hz, H-9), 4.52 (d, 1H, 
J15a,15b = 11.8 Hz, H-15a), 4.27 (d, 1H, H-15b), 3.46 – 3.34 (m, 2H, H-10, 
H-12), 3.29 (s, 3H, OMe), 2.82 (t, 1H, JOH,12 = 1.3 Hz, OH), 2.51 (q, 1H, J 
= 7.4 Hz), 2.39 – 2.26 (m, 2H), 2.28 – 2.18 (m, 1H, H-7), 2.11 – 2.00 (m, 
1H, H-7’), 1.81 (d, 3H, C-14Me), 1.74 – 1.55 (m, 2H), 1.50 – 1.33 (m, 2H, 
H-6,6’), 1.30 – 1.10 (m, 2H), 0.96 (d, 3H, C-12Me); 13C NMR(CDCl3, 125 
MHz): δ 175.0 (C-2), 136.7 (C-8), 136.3 (C-13), 128.2 (C-14), 128.0  (C-
9), 84.0 (C-11 or C-10), 76.0 (C-11 or C-10), 64.0 (C-15), 56.2 (OMe), 
35.1 (CH2), 32.9 (C-12), 32.0 (C-7), 27.6 (CH2), 27.4 (C-6), 25.8 (CH2), 
23.5 (Me), 13.2 (Me). HRMS-ESI: calcd for C17H28O4Na: 319.1885; 
Found: 319.1882. 
(4Z,6R,7S,8S,9E)-7-hydroxy-8-methoxy-4,6-dimethylcyclopentadeca-
4,9-dienone (MGSTA-9). Purification by FC (PE/EtOAc 10:1) afforded 
MGSTA-9 (11.8 mg, 82%) as a white syrup; [α]
D 
87° (c 0.9, CHCl
3
); 1H 
NMR(CDCl3, 500 MHz): δ 5.66 (ddd, 1H, J 14.7, 8.8, 5.2 Hz, H-10), 5.41 
(d, 1H, J5,6 = 9.6 Hz, H-5), 5.17 (dd, 1H, J8,9 = 7.3 Hz, H-9), 3.44–3.33 (m, 
2H, H-7,8), 3.28 (s, 3H, OMe), 2.78 (d, 1H, J7,OH = 1.3 Hz, OH), 2.51–
2.31 (m, 5H), 2.29–2.17 (m, 2H), 2.14–2.01 (m, 2H), 1.73–1.56 (m, 5H), 
1.52–1.34 (m, 2H), 1.29–1.08 (m, 2H), 0.93 (d, 3H, J6,Me = 6.8 Hz, 
C6Me); 13C NMR(CDCl3, 125 MHz): δ 213.0 (C-1), 136.5 (C-10), 133.4 
(C-4), 129.8 (C-5), 128.1 (C-9), 84.2 (C-7 or C-8), 76.6 (C-7 or C-8), 56.3 
(OMe), 43.1 (CH2), 41.8 (CH2), 32.7 (C-6), 31.8 (CH2), 27.9 (CH2), 27.8 
(CH2), 26.4 (CH2), 25.7 (CH2), 23.4 (Me at C-4), 13.0 (Me at C-6). 
HRMS-ESI: calcd for C18H30O3Na: 317.2093; Found: 317.2087. 
(2R,3R,4S)-2,4-dimethylhex-5-ene-1,3-diol (26). To stirred t-BuOK 
(1.63 g; 14.57 mmol) in THF (4 mL) at -45oC n-butyllithium in heptane 
(9.1 mL, 14.57 mmol, 1.6 M) was added. The mixture was cooled to -
78oC and β-methoxydiisopinocampheylborane (5.5 g, 17.4 mmol) in THF 
(17 mL) was added via cannula over The mixture was stirred at -78oC for 
an additional 1h and boron trifluoride etherate (2.4 mL, 19.45 mmol) was 
added dropwise at -78oC. Immediately, a solution of aldehyde 25 (3.94 g, 
20.52 mmol) in THF (7 mL) was added, and the mixture was stirred at -
78oC for 18 h. Then aqueous NaOH (10.66 mL; 32 mmol, 3M) was added 
followed by H2O2 (4.5 mL, 30%), and the biphasic mixture was allowed to 
warm to room temperature slowly and refluxed for 1h. The solution was 
diluted with CH2Cl2 and washed with water. Organic layer was separated, 
and then dried over Na2SO4 and the solvent was removed under reduced 
pressure. The residue was subjected to silica gel chromatography (PE: 
EtOAc, 1:6) affording a mixture of the title compound and pinenol during 
the work-up (9.87 g) which can be used directly in the next step. The 
mixture (9.87 g) was dissolved in dry methanol (200 mL) and K2CO3 
(2.32 g) was added. After stirring at room temperature for 24 h AcOH 
was added until the pH = 7. The solvent was removed under reduced 
pressure and the residue was purified by chromatography (PE: EtOAc 
1:10 Et2O) to afford 26 (940 mg; 32% from 25) as white crystal 
(needles);  Mp = 175-181 oC; 1H NMR (CDCl3, 500MHz) δ 5.62 (ddd, 1H, 
J5,6trans = 17.1, J5,6cis = 10.3, J4,5 = 8.7 Hz, H-5), 5.08 – 5.04 (m, 1H, H-
6trans), 4.98 (dd, 1H, Jgem = 1.8 Hz, H-6cis), 3.71 (dd, 1H, J1,1’ = 10.5, J1,2 = 
4.1 Hz, H-1), 3.66 (dd, 1H, J1’,2 = 5.5 Hz, H-1’), 3.56 (dd, 1H, J3,4 = 9.1, 
J2,3 = 2.4 Hz, H-3), 2.67 (bs, 2H, OH), 2.33 – 2.26 (m, 1H, H-4), 1.82 
(dddd, 1H, J2,Me = 6.8 Hz, H-2), 1.09 (d, 3H, J4,Me = 6.7 Hz, CH3 at C-4), 
0.93 (d, 3H, CH3 at C-2); 13C NMR (CDCl3, 125 MHz) δ 141.0 (C-5), 
114.9 (C-6), 77.5 (C-3), 67.9 (C-1), 42.4 (C-4), 36.7 (C-2), 17.3 (CH3 at 
C-4), 9.1 (CH3 at C-2); HRMS-ESI: calcd for C8H15O2Na: 143.1072; 
Found: 143.1071.  
Ring-Closing Metathesis on MGSTA-10. To a stirred solution of 
MGSTA-10 (100 mg; 0.33 mmol), in degassed PhCH3 (650 mL) the 
Grubbs II catalyst (57 mg, 0.067 mmol)  was added via canula. The 
mixture was stirred at reflux for 60 min. The PhCH3 was removed under 
reduced pressure. Purification of the residue by FC (EtOAc/Cy 1:30) 
afforded MGSTA-11 (25 mg, 31%) and MGSTA-12 (23.1 mg; 33%) as 
yellow syrups. 
(9S,10R,11R,Z)-10-(methoxymethoxy)-9,11-dimethyloxacyclododec-
7-en-2-one (MGSTA-11). 1H NMR (CDCl3, 500MHz) δ 5.48 – 5.40 (m, 
1H, H-8), 5.34 (td, 1H, J7,8 = 10.6, J6,7 = 5.0 Hz, H-7), 4.67 (d, 1H, J = 6.6 
Hz, OCH2O), 4.62 (d, 1H, J = 6.6 Hz, OCH2O), 4.38 (dd, 1H, J12,12’ = 11.4, 
J12,11 = 3.1 Hz, H-12), 3.89 (dd, 1H, J11,12’ = 5.2 Hz, H-12’), 3.43 – 3.38 (m, 
4H, H-10,OCH3), 2.71 (dqd, 1H, J8,9 = 9.9, J9,Me = 6.8, J9,10 = 2.9 Hz, H-9), 
2.44 (ddd, 1H, J = 12.7, 8.5, 3.9 Hz, CH2), 2.33 (ddd, 1H, J = 13.3, 8.9, 
3.7 Hz, CH2), 2.26 – 2.14 (m, 1H, CH2), 2.14 – 2.02 (m, 1H, H-11), 1.91 – 
1.75 (m, 2H, CH2), 1.64 (dddt, 2H, J = 20.6, 8.7, 5.8, 3.2 Hz, CH2), 1.42 – 
1.29 (m, 1H, CH2), 1.11 (d, 3H, J = 7.3 Hz, CH3 at C-11), 0.98 (d, 3H, J = 
6.8 Hz, H- CH3 at C-9); 13C NMR (CDCl3, 125 MHz) δ 174.5 (C-2), 135.8 
(C-8), 128.6 (C-7), 98.3 (OCH2O), 85.6 (C-10), 67.4 (C-12), 56.3 (OCH3), 
36.2 (C-11), 34.6 (CH2), 34.5 (C-9), 28.8 (CH2), 25.9 (CH2), 23.6 (CH2), 
15.1 (CH3 at C-11), 14.6 (CH3 at C-9); HRMS-ESI: calcd for C15H26O4Na: 
293.1729; Found: 293.1731. 
(9S,10R,11R,E)-10-(methoxymethoxy)-9,11-dimethyloxacyclododec-
7-en-2-one (MGSTA-12). 1H NMR (CDCl3, 500MHz) δ 5.42 (ddd, 1H, J7,8 
= 14.9, 8.3, 6.3 Hz, H-7), 5.25 (dd, 1H, J8,9 = 8.2 Hz, H-8), 4.70 – 4.66 (m, 
2H, OCH2O), 4.47 (dd, 1H, J12,12’ = 10.6, J11,12 = 2.9 Hz, H-12), 3.54 (appt, 
1H, J12,12’ = J11,12’ = 10.7 Hz, H-12’), 3.40 (s, 3H, OCH3), 3.32 (d, 1H, J = 
10.1 Hz, H-10), 2.46 – 2.38 (m,1H, CH2), 2.17 – 2.06 (m, 3H, H-9 and 
CH2), 2.02 – 1.93 (m, 1H, H-11), 1.74 – 1.61 (m, 4H, CH2), 1.20 – 1.12 
(m, 1H, CH2), 1.06 (d, 3H, J = 6.8 Hz, CH3 at C-9), 0.89 (d, 3H, J=7.3 Hz, 
CH3 at C-11); 13C NMR (CDCl3, 125 MHz) δ 173.4 (C-2), 135.5 (C-7), 
131.4 (C-8), 98.7 (OCH2O), 83.9 (C-10), 66.5 (C-12), 56.0 (OCH3), 40.4 
(C-9), 35.7 (C-11), 34.7 (CH2), 30.4 (CH2), 26.9 (CH2), 22.6 (CH2), 17.2 
(CH3 at C-9), 10.6 (CH3 at C-11); HRMS-ESI: calcd for C15H26O4Na: 
293.1729; Found: 293.1732. 
(9S,10R,11R,Z)-10-hydroxy-9,11-dimethyloxacyclododec-7-en-2-one 
(MGSTA-13). To stirred MGSTA-11 (28.1 mg; 0.104 mmol) in CH2Cl2 (5 
mL), TMSBr (20.6 µL; 0.0156 mmol) was added at –20oC. The mixture 
was stirred for 1 h. Satd NaHCO3 was then added and the solution was 
extracted with CH2Cl2 (3x10mL). The combined organic layers were dried 
and the solvent was removed under reduced pressure. Purification by FC 
(EtOAc/Cy 1:8) gave MGSTA-13 (18.2 mg, 77 %) as a colourless oil. 
[α]D -20o (c 1.5, CHCl3); 1H NMR (CDCl3, 500MHz) δ 5.54 – 5.47 (m, 1H, 
H-8), 5.39 (td, 1H, J7,8 = 10.6, J6,7 = 5.3 Hz, H-7), 4.47 (dd, 1H, J12,12’ = 
11.5, J12,11 = 3.4 Hz, H-12), 3.82 (dd, 1H, J11,12’ = 4.5 Hz, H-12’), 3.54 
(ddd, 1H, J10,11=7.6, J10,OH = 4.9, J9,10 = 2.2 Hz, H-10), 2.73 (dqd, 1H, J8,9 
= 9.2, J9,Me = 6.8 Hz, H-9), 2.42 (ddd, 1H, J = 12.9, 8.8, 4.0 Hz, CH2), 
2.33 (ddd, 1H, J = 13.1, 8.8, 3.7 Hz, CH2), 2.24 – 2.14 (m, 1H, CH2), 2.01 
– 1.93 (m, 1H, H-11), 1.91 – 1.84 (m, 1H, CH2), 1.83 – 1.74 (m, 1H, CH2), 
1.70 – 1.63 (m, 2H, CH2), 1.43 (d, 1H, OH), 1.37 – 1.28 (m, 1H, CH2), 
1.14 (d, 3H, J11,Me=7.0 Hz, CH3 at C-11), 0.96 (d, 3H, CH3 at C-9) ;13C 






NMR (CDCl3, 125 MHz) δ 174.6 (C-2), 135.5 (C-8), 128.9 (C-7), 78.4 (C-
10), 67.4 (C-12), 36.3 (C-11), 34.8 (CH2), 33.8 (C-9), 28.8 (CH2), 26.1 
(CH2), 23.7 (CH2), 15.0 (CH3 at C-11), 12.8 (CH3 at C-9); HRMS-ESI: 
calcd for C15H25NO3Na: 290.1732; Found: 290.1726. 
(9S,10R,11R,E)-10-hydroxy-9,11-dimethyloxacyclododec-7-en-2-one 
(MGSTA-14). To stirred MGSTA-12 (23.4 mg; 0.087 mmol) in CH2Cl2 (6 
mL), TMSBr (23 µL; 0.174 mmol) was added at –20oC. The mixture was 
stirred for 2 h. Satd NaHCO3 was added and the solution was extracted 
with CH2Cl2 (3 x 10mL) and the combined organic layers were dried and 
the solvent was removed under reduced pressure. Purification by FC 
(EtOAc/Cy 1:10) gave MGSTA-14 (14.5 mg, 74 %) as a colourless oil. 
[α]D 6.49o (c 0.99, CHCl3); 1H NMR (CDCl3, 500MHz) δ 5.44 (ddd, 1H, 
J7,8 = 14.6, J7,6 = 8.0, J7,6’ = 6.4 Hz, H-7), 5.28 (dd, 1H, J8,9 = 8.1 Hz, H-8), 
4.41 (dd, 1H, J12,12’ = 10.7, 2.8 Hz, H-12), 3.56 (t, 1H, H-12’), 3.43 (dd, 
1H, J = 9.7, J10,OH = 6.4 Hz, H-10), 2.44 – 2.36 (m, 1H, CH2), 2.16 – 2.06 
(m, 3H, H-9 and CH2), 2.03 – 1.96 (m, 1H, H-11), 1.74 – 1.62 (m, 4H, 
CH2), 1.45 (d, 1H, OH), 1.20 – 1.12 (m, 1H, CH2), 1.09 (d, 3H, J9,Me = 6.8 
Hz, CH3 at C-9), 0.88 (d, 3H, J11,Me=7.3 Hz, CH3 at C-11); 13C NMR 
(CDCl3, 125 MHz) δ 173.4 (C-2), 135.3 (C-8), 131.2 (C-7), 76.3 (C-10), 
66.6 (C-12), 39.9 (C-9), 35.9 (C-11), 34.9 (CH2), 30.2 (CH2), 27.4 (CH2), 
22.5 (CH2), 16.8 (CH3 at C-9), 10.0 (CH3 at C-11); HRMS-ESI: calcd for 
C13H22O3Na: 249.1467; Found: 249.1459. 
(7E,9S,10R,11R,12Z)-10-hydroxy-9,11,13-
trimethyloxacyclotetradeca-7,12-dien-2-one (MGSTA-15). To a stirred 
solution of 34 (8.7 mg; 0.028 mmol) in CH2Cl2 (5 mL), TMSBr (5.5 µL; 
0.042 mmol) was added at –15oC. The mixture was stirred for 3h. Satd 
NaHCO3 was added and the solution was extracted with CH2Cl2 (3 x 10 
mL). The combined organic layers were dried and the solvent was 
removed under reduced pressure. Purification by FC (EtOAc/Cy 1:7) 
gave MGSTA-15 (4.5 mg, 60%) as a colourless oil; [α]D 37.6o (c 0.19, 
CHCl3); 1H NMR (CDCl3, 500MHz) δ 5.60 (dt, 1H, J11,12 = 10.2, J12,Me = 
1.4 Hz, H-12), 5.46 (ddd, 1H, J7,8 = 15.3, J = 7.8, J = 5.8 Hz, H-7), 5.30 
(ddt, 1H, J = 8.6, J = 1.3 Hz, H-8), 4.56 (dd, 1H, J14,14’ = 13.1, J = 1.0 Hz, 
H-14), 4.34 (d, 1H, H-14’), 3.24 (d, 1H, J = 9.3 Hz, H-10), 3.02 – 2.95 (m, 
1H, H-11), 2.46 – 2.39 (m, 1H, CH2), 2.30 – 2.18 (m, 2H, H-9 and CH2), 
2.17 – 2.10 (m, 1H, CH2), 1.98 – 1.90 (m, 1H, CH2), 1.82 – 1.77 (m, 1H, 
CH2), 1.76 (d, 3H, CH3 at C-13), 1.64 – 1.57 (m, 1H, CH2), 1.53 – 1.47 (m, 
1H, CH2), 1.41 – 1.32 (m, 1H CH2), 1.09 (d, 3H, J9,Me = 6.7 Hz, CH3 at C-
9), 0.92 (d, 3H, J11,Me = 7.0 Hz, CH3 at C-11); 13C NMR (CDCl3, 125 MHz) 
δ 174.0 (C-2), 134.7 (C-12), 133.9 (C-8), 129.9 (C-7), 127.5 (C-13), 78.9 
(C-10), 65.0 (C-14), 41.4 (C-9), 34.6 (C-11), 34.0 (CH2), 30.0 (CH2), 27.6 
(CH2), 23.5 (CH2), 23.4 (CH3 at C-13), 18.1 (CH3 at C-9), 12.9 (CH3 at C-
11); HRMS-ESI: calcd for C16H26O3Na: 289.1780; Found: 289.1775. 
(4Z,6R,7S,8S,9E)-7-O-(methyl 2’,3’,4’-tri-O-benzoyl--D-
glucopyranosyluronate)-4,6-dimethylcyclotetradeca-8-methoxy-4,9-
dienone (37). To stirred macroketone MGSTA-5  (5 mg, 18 mol), the 
trichloroacetimidate 36 (24 mg, 36 mol), and powdered molecular 
sieves 4 A (25 mg) in dry CH2Cl2 (0.5 mL) was cooled to – 40 oC under 
nitrogen atmosphere. To this mixture was added 10% TMSOTf in CH2Cl2 
(11 L, 7.2 mol) drop wisely, and the mixture was stirred at – 40 oC for 5 
h, and then EtOAc was added (1 L, 7.2 mol). The mixture was filtered 
and concentrated. FC of the residue (PE/EtOAc 4:1) gave 37 (8 mg, 
57%); [α]
D 
-9.4° (c 0.58, CHCl
3
); 1H NMR(CDCl3, 500 MHz): δ 8.00-8.00 
(m, 2H, ArH), 7.93-7.91 (m, 2H, ArH), 7.88 - 7.81 (m, 2H, ArH), 7.53 - 
7.36 (m, 7H, ArH), 7.31-7.28 (m, 2H, ArH), 5.94 (appt, 1H, J2’,3’ =J3’,4’ = 
9.6 Hz, H-3’), 5.69 (dd, 1H, J3’,4’ = J4’,5’ = 9.7 Hz, H-4’), 5.62 – 5.52 (m, 3H, 
H-2’, H-5,10), 5.23 (dd, 1H, J9,10trans = 15.7, J8,9 = 7.5 Hz, H-9), 5.21 (d, 
1H, J1’,2’ = 7.9 Hz, H-1’), 4.27 (d, 1H, H-5’), 3.69 (s, 3H, OMe), 3.48 – 
3.38 (m, 2H, H-7,8), 2.87 (s, 3H, OMe), 2.56 – 2.41 (m, 2H, H-6, CH2), 
2.40 – 2.30 (m 2H, CH2), 2.28 – 2.06 (m, 5H, CH2), 1.70 (d, 3H, J = 1.5 
Hz, Me at C-4), 1.68 – 1.57 (m, 2H, CH2), 1.52 – 1.45 (m, 2H, CH2), 0.91 
(d, 3H, J6,Me = 6.8 Hz, Me at C-6); 13C NMR (125 MHz, CDCl3): δ 212.3 
(C-1), 167.6 (C=O), 165.9 (C=O), 165.4 (C=O), 165.0 (C=O), 134.5 
(C=C), 133.5 (ArCH), 133.4 (ArCH), 133.2 (ArCH), 132.0  (Cq), 130.5 
(C=C), 130.0 (ArCH), 130.0 (ArCH), 129.9 (ArCH), 129.8 (Cq), 129.4 (C-
9), 129.1 (Cq), 129.1 (Cq), 128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 
101.5 (C-1’) , 84.9 (C-7 or 8), 84.5 (C-7 or 8), 72.9 (C-5), 72.7 (C-3’), 
72.1 (C-2’), 70.8 (C-4’), 56.5 (OCH3), 52.9 (OCH3), 42.3 (CH2), 41.0 
(CH2), 33.2 (C-6), 30.5 (CH2), 28.8 (CH2), 27.2 (CH2), 23.4 (CH2), 23.2 
(CH3 at C-4), 13.5 (CH3 at C-6); HRMS-ESI: calcd for C45H50O12Na: 
805.3200; Found: 805.3202. 
(4Z,6R,7S,8S,9E)-7-O-(-D-glucopyranosyluronic acid)-4,6-
dimethylcyclotetradeca-8-methoxy-4,9-dienone (MGSTA-16). To 
stirred 37 (12.7 mg; 16 µmol) in MeOH (1.2 mL), NaOH(aq) 5% (48 µL, 59 
µmol) wad added. The resulting solution was stirred at RT for 20 h.  A 
solution of 1M AcOH was added until the pH was 7. The solvent was 
removed under reduced pressure and the residue was passed through 
silica gel 100 C18-reversed phase column (H2O to H2O/MeOH 4:1 to 
H2O/MeOH 2:1 to H2O/MeOH 1:1 to H2O/MeOH 1:2 to MeOH). The 
residue was subjected to vacuum distillation to remove the aromatic 
impurities and then passed again through silica gel 100 C18-reverse 
phase  silica (eluant, H2O to H2O/MeOH 4:1 to H2O/MeOH 2:1 to 
H2O/MeOH 1:1 to H2O/MeOH 1:2 to MeOH) to give MGSTA-16 (5.3 mg; 
73%); [α]
D 
+5.32° (c 0.36, MeOH); 1H NMR (CDCl3, 500 MHz): 5.85 (ddd, 
1H, J9,10 = 15.0, 9.6, 4.8 Hz, H-10), 5.44 (dd, 1H, J8,9 =  9.0 Hz, H-9), 
5.37 (d, 1H, J5,6 = 9.2 Hz, H-5), 4.44 (d, 1H, J1’,2’ = 7.9 Hz, H-1’), 3.85 
(appt, 1H, H-8), 3.60 (d, 1H, J4’,5’ = 9.3 Hz, H-5’), 3.56–3.46 (m, 3H, H-
7,3’,4’), 3.37 (dd, 1H, J2’,3’ = 7.8 Hz, H-2’), 3.32 (s, 3H, OCH3), 2.96 (m, 
1H, CH2), 2.69 (m, 1H, CH2), 2.42 (m, 1H, CH2), 2.35–2.16 (m, 6H, CH2, 
H-6), 1.71–1.60 (m, 5H, Me at C-4, CH2), 1.50 (m, 1H, CH2), 1.36–1.25 
(m, 1H, CH2), 0.87 (d, 3H, JMe,6 = 6.7 Hz, Me at C-6); 13C NMR (125 MHz, 
CDCl3): δ 218.8 (C-1), 175.4 (C-6’), 137.2 (C-10), 133.1 (C-4), 130.5 (C-
5), 127.0 (C-9), 104.3 (C-1’), 87.7 (CH), 84.4 (C-8), 76.9 (C-5’), 75.4 (CH), 
73.8 (C-2’), 71.9 (CH), 55.5 (OCH3), 40.4 (CH2), 38.7 (CH2), 32.9 (C-6), 
29.1 (CH2), 28.6 (CH2), 24.7 (CH2), 22.1 (Me at C-4), 20.5 (CH2), 12.2 




dienone (38). To stirred 37 (20.8 mg; 27 µmol), in CDCl3 (0.75 mL), TiCl4 
(66 µL; 54µmol; 0.82 M in CDCl3) was added. After storage for 12h at 4 
oC, the solution was diluted with CH2Cl2 and quenched with NaHCO3. 
The organic layers were collected, dried over Na2SO4, filtered and the 
solvent was removed under reduced pressure. FC of the residue 
(PE/EtOAc 4:1) gave 38 (14.5 mg, 69%); [α]
D 
+33.4° (c 0.75, CHCl
3
); 1H 
NMR(CDCl3, 500 MHz): δ 8.05–7.99 (m, 2H, ArH), 8.00–7.94 (m, 2H, 
ArH), 7.92–7.85 (m, 2H, ArH), 7.56–7.48 (m, 2H, ArH), 7.47–7.35 (m, 5H, 
ArH), 7.30 (m, 2H, ArH), 6.27 (appt, 1H, J2’,3’ = J3’,4’ = 9.9 Hz, H-3’), 5.71 
(ddd, 1H, J9,10 = 14.9, 8.4, 5.9 Hz, H-10), 5.58 (t, 1H, J4’,5’ = 10.0 Hz, H-
4’), 5.45 (d, 1H, J1’,2’ = 3.7 Hz, H-1’), 5.37 (dd, 1H, H-2’), 5.31 (dd, 1H, J8,9 
= 8.1 Hz, H-9), 5.21 (d, 1H, H-5’), 4.80 (d, 1H, J5,6 = 9.6 Hz, H-5), 3.70 
(appt, 1H, H-8), 3.67 (s, 3H, OCH3), 3.56 (d, 1H, J7,8 = 9.1 Hz, H-7), 3.27 
(s, 3H, OCH3), 2.63-2.57 (m, 1H, CH2), 2.38–2.07 (m, 7H, H-6, CH2), 
1.98-1.93 (m, 1H, CH2), 1.67–1.57 (m, 2H, CH2), 1.48-1.38 (m, 2H, CH2), 
1.42 (d, 3H, JMe,4 = 5.8 Hz, Me at C-4), 0.85 (d, 3H, JMe,6 = 6.6 Hz, Me at 
C-6); 13C NMR (125 MHz, CDCl3): δ 211.1 (C-1), 169.1 (C=O), 166.0 






(C=O), 165.7 (C=O), 165.6 (C=O), 134.9 (C-10), 134.0 (Cq), 133.7 
(ArCH), 133.4 (ArCH), 133.4 (ArCH), 130.1 (ArCH), 129.9 (ArCH), 129.9 
(ArCH), 129.6 (C-5), 129.3 (Cq), 129.3 (Cq), 129.1 (C-9), 129.0 (Cq), 
128.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 97.3 (C-1’), 86.2 (C-7), 82.6 
(C-8), 71.8 (C-2’), 70.9 (C-4’), 70.0 (C-3’), 68.7 (C-5’), 56.1 (OCH3), 52.8 
(OCH3), 40.8 (CH2), 40.3 (CH2), 33.9 (C-6), 30.2 (CH2), 29.0 (CH2), 26.3 
(CH2), 22.8 (Me at C-4), 22.2 (CH2), 12.8 (Me at C-6); HRMS-ESI: calcd 
for C45H50O12Na: 805.3200; Found: 805.3212. 
(4Z,6R,7S,8S,9E)-7-O-(α-D-glucopyranosyluronic acid)-4,6-
dimethylcyclotetradeca-8-methoxy-4,9-dienone (MGSTA-17). To 
stirred 38 (9 mg; 11.5 µmol) in MeOH (0.8 mL), NaOH(aq) 5% (26.2 µL, 
32.2 µmol) wad added. The resulting solution was stirred at RT for 48 h. 
A solution of 1M AcOH was added until the pH = 7. The solvent was 
removed under reduced pressure and the residue was passed through a 
silica gel 100 C18-reversed phase column (eluant, H2O to H2O/MeOH 4:1 
to H2O/MeOH 2:1 to H2O/MeOH 1:1 to H2O/MeOH 1:2 to MeOH) to give 
MGSTA-17 (3.2 mg; 61%); [α]
D 
+63.2 (c 0.032, MeOH); 1H NMR (CDCl3, 
500 MHz): 5.81 (ddd, 1H, J9,10 = 15.0, 10.1, 4.5 Hz, H-10), 5.46-5.39 (dd, 
1H, J8,9 = 9.4 Hz, H-9), 5.34 (dd, 1H, J = 9.9, 1.6 Hz, H-5), 5.01 (d, 1H, 
J1’,2’ = 3.9 Hz, H-1’), 4.39 (d, 1H, J4’,5’ = 10.2 Hz, H-5’), 3.81 (dd, 1H, J2’,3’ 
= 9.9, J3’,4’ = 8.9 Hz, H-3’) 3.74-3.71 (appt, 1H, H-8’), 3.56 (m, 2H, H-7,2’), 
3.48 (dd, 1H, J3’,4’ = 9.0 Hz, H-4’), 3.29 (s, 3H, OCH3), 3.12–3.05 (m, 1H, 
CH2), 2.78-2.73 (m, 1H, CH2), 2.58–2.52 (m, 1H, CH2), 2.36–2.10 (m, 6H, 
H-6, CH2), 1.72-1.62 (m, 2H, CH2), 1.70 (d, 3H, J = 1.4 Hz, Me at C-4), 
1.53–1.44 (m, 1H, CH2), 1.27–1.13 (m, 1H, CH2), 0.89 (d, 3H, J6,Me = 6.7 
Hz, Me at C-6); 13C NMR (125 MHz, CDCl3): δ 218.4 (C-1), 175.7 (C-6’), 
136.8 (C-10), 133.4 (C-4), 130.6 (C-5), 127.3 (C-9), 99.2 (C-1’), 84.4 (C-
7), 83.2 (C-8), 72.6 (C-3’), 71.9 (C-4’), 71.5 (C-2’), 71.3 (C-5’), 55.3 
(OCH3), 40.3 (CH2), 37.8 (CH2), 33.8 (C-6), 29.0 (CH2), 28.7 (CH2), 24.2 
(CH2), 22.0 (Me at C-4), 19.9 (CH2), 12.0 (Me at C-6); HRMS-ESI: calcd 
for C23H36O9Na: 479.2257; Found: 479.2256. 
MGSTA-18 and MGSTA-19.  
To 57b (21 mg, not fully pure, <32.5 μmol,) at -78°C in 2.5 mL CH2Cl2,  
mCPBA (≤77%, 7.6 mg, 33.9 μmol) in CH2Cl2 (2.5 mL) was added. After 
30 minutes at -78°C, TLC (PE/EtOAc 1:1.5) showed only baseline 
material. iPr2NEt (6.8 μL, 39 μmol) was then added and the mixture was 
allowed to warm to room temperature over 10 minutes. After 2 hour at 
room temperature, TLC showed there still have baseline material, so 
more iPr2NEt (7 μL) was added. After 1 h the mixture was concentrated 
under reduced pressure and purified by chromatography on silica eluting 
with PE-EtOAc (1:1.5) to give MGSTA-19 (4.7 mg) and MGSTA-18 (8.5 
mg) in 65% yield for 2 steps. 
Analytical data for 4-((S)-5-((2R,3E,5R,6S,7S,8Z,12Z)-6-hydroxy-7-
methoxy-3,5-dimethyl-14-oxooxacyclotetradeca-3,8,12-trien-2-yl)-4-
oxohexyl)piperidine-2,6-dione (MGSTA-18): 1 H NMR (500 MHz), δ 
7.70 (br s, 1 H), 6.23 (ddd, 1 H, J = 11 Hz, 11 Hz, 6.5 Hz, CH=CHC=O, 
H-3), 5.78 (ddd, 1 H, J = 11 Hz, 11 Hz, 5.3 Hz, H-8), 5.72 (d, 1 H, J = 
11.4 Hz, H-4), 5.55 (apt t, 1 H, J = 10.5 Hz, H-7), 5.51 (d, 1 H, J = 10 Hz, 
H-11), 5.39 (d, 1 H, J = 11.0 Hz, CHOC=O), 3.79 (d, 1 H, J = 10.1 Hz), 
3.19 (s, 3 H), 3.04 (t, 1 H, J = 10.2 Hz, 10.2 Hz), 3.00 (dd, 1 H, J = 11.1 
Hz, 7.1 Hz), 2.80-2.68 (m, 4 H), 2.52 (dt, 2 H, J = 6.9 Hz, 6.8 Hz, 3.3 Hz), 
2.30-2.19 (m, 2 H), 2.17-2.06 (m, 3 H), 1.96 (m, 1 H), 1.63 (d, 3 H, J = 
1.0 Hz), 1.65-1.60 (m, 2 H), 1.40-1.33 (m, 2 H), 1.08 (d, 3 H, J = 6.6 Hz), 
0.97 (d, 3 H, J = 7.1 Hz); 13 C NMR (125 MHz), δ 210.9 (C), 171.7 (C), 
165.5 (C), 145.1 (CH), 139.6 (CH), 133.7 (CH), 129.5 (C), 127.0 (CH), 
121.4 (CH), 81.7 (CH), 77.2 (CH), 73.1 (CH), 54.9 (CH3), 46.6 (CH), 41.3 
(CH2), 37.7 (CH2), 35.9 (CH), 34.2 (CH2), 30.4 (CH), 29.8 (CH2), 28.3 
(CH2), 20.1 (CH2), 17.2 (CH3), 13.4 (CH3), 10.5 (CH3); ESI/MS- (m/z): 
512.26 (M+Na+), 488.27 (M-H-); HRMS-ESI: calcd for C27H39NO7Na: 
512.2624, Found: 512.2598. 
Analytical data for 4-((S)-5-((2R,3E,5R,6S,7S,8Z,12E)-6-hydroxy-7-
methoxy-3,5-dimethyl-14-oxooxacyclotetradeca-3,8,12-trien-2-yl)-4-
oxohexyl)piperidine-2,6-dione (MGSTA-19): 1 H NMR (500 MHz), δ 
7.75 (br s, 1 H, NH), 6.84 (ddd, 1 H, J = 15.5 Hz, 6.0 Hz, 7.0 Hz, 
CH=CHC=O, H-3), 5.85 (d, 1 H, J = 15.5 Hz, CH=CHC=O, H-2), 5.69 
(ddd, 1 H, J = 11 Hz, 11 Hz, 5.5 Hz, H-6), 5.59 (dd, 1 H, J = 11 Hz, 9.5 
Hz, H-7), 5.34 (d, 1 H, J = 10.0 Hz, CH3C=CH, H-11), 5.24 (d, 1 H, J = 
10.4 Hz, CH-O-C=O, H-13); 13C-NMR (125 MHz), δ 211.1 (C), 171.8 (C), 
167.0 (C), 150.7 (CH), 136.2 (CH), 133.1 (CH), 131.6 (C), 127.8 (CH), 
123.0 (CH), 82.7 (CH), 77.5 (CH), 74.8 (CH), 55.5 (CH3), 47.2 (CH), 41.1 
(CH2), 37.73 (CH2), 37.72 (CH2), 35.6 (CH), 34.0 (CH2), 30.4 (CH2), 
30.3 (CH), 29.3 (CH2), 20.0 (CH2), 17.6 (CH3), 13.5 (CH3), 11.4 (CH3); 
ESI/MS- (m/z): 512.26 (M+Na+), 488.27 (M-H-); HRMS-ESI: calcd for 
C27H39NO7Na: 512.2624, Found: 512.2621.  
Cell viability assay (MTT-assay): Cell viability (metabolic activity of 
viable cells) was quantified by MTT assay. Cells were seeded onto 96-
well plate (Nunc Inc., Denmark) at the concentration of 1 × 104 cells per 
well. When cells reached 60-70% confluence, the medium (DMEM) was 
replaced with medium containing 10% FBS and six various migrastatin 
analogues at the concentrations of: 1, 10 or 100 μM. The cultures were 
incubated for 24 hours. Then, cells were incubated with 0.5 mg/ml 
tetrazolium salt MTT diluted in phenol red-free DMEM medium (Sigma 
Aldrich) for 4 h at 37°C. To complete solubilization of the formazan 
crystals, 100 μl of DMSO (Dimethyl sulfoxide, Sigma Aldrich) were added 
to each well. Cell viability was quantified by measuring photometric 
absorbance at 570 nm in a multi-well plate reader (Infinite 200 PRO 
Tecan™, TECAN, Switzerland). All the samples were examined in 
triplicate, each experiment was conducted three times (n= 9).  
In vitro wound healing assay (scratch test): the scratch assay was 
conducted to assess the influence of migrastatin analogues on MCF7, 
MCF7-Dox, MDA-MB361, MDA-MB231, HPAC cancer cell motility. The 
cells were seeded in a high density at 600 mm Petri dishes (Corning-
Costar, Cambridge, USA). After 24 hrs, the medium was removed and 
replaced with medium (DMEM) containing 10% FBS and one migrastatin 
analogues or DMSO (control). The monolayer was wounded by 
scratching the surface: as uniformly and straight as possible with a 
pipette tip (1000 μl) at least three times. The images of cells invading the 
scratch were captured at indicated time points (0, 6 and 24 or 48 hrs 
where indicated) using phase contrast microscopy (IX 70 Olympus 
Optical Co., Germany). The pictures were analyzed using a computer-
assisted image analyzer (Olympus Microimage™ Image Analysis, 
software version 4.0 for Windows, USA). The migration rate was 
expressed as percentage of scratch closure and was calculated as 
follows: % of scratch closure= a-b/a, where (a) is a distance between 
edges of the wound, and (b) is the distance which remained cell-free 
during cell migration to close the wound[39]. The values are presented as 
means of three independent wound fields from three independent 
experiments (n= 9).  
Trans-well migration assay: The Boyden chamber cell migration assay 
was performed using the BD Falcon™ FluoroBlock™ 24-Multiwell Insert 
Plates (8 micron pore size) (BD Biosciences, USA). Firstly, cells (1×105) 
were suspended in FBS free medium and added to the apical chambers 
of an insert plates (500 μl). Then 750 μl of chemoattractant (10% FBS) 
was added to the basal chambers. Migrastatin analogues or DMSO (as a 
control) were added to the medium in both chambers. For dose-
dependent studies MGSTA analogues were used in the range of 






concentration from 0.01 to 100 μM. Migration assays were carried out for 
18-20 h at standard culture conditions. Then, medium was carefully 
removed from apical chamber and the insert system was transferred into 
a second 24-well plate containing 500 μl of 2.5 μg/ml Calcein AM in 
Hanks’ Balanced Salt solution (HBSS). Plates were incubated for one 
hour at standard culture conditions. Then, the fluorescence of migrated 
cells was measured at excitation wavelength 485 nm and emission 
wavelength 530 nm using florescent plate reader with bottom reading 
capabilities Infinite 200 PRO Tecan™ (TECAN, Switzerland). All samples 
were assayed in triplicate, and each experiment was conducted three 
times (n= 9). For each experiment two negative controls were used: (1) 
cells grown as given above without adding chemoattractant to the 
medium, and (2) medium added as described without cells. In order to 
determine fluorescence of cells that migrated through the membrane, 
plates were analysed using a fluorescence microscope (Olympus BX60, 
magnification x4). 
In vitro pharmacology: Binding assays: Cell membrane  homogenates 
are incubated with radioligand binding in the absence or presence of 
MGSTA-6 in a buffer. Non specific binding is determined in the presence 
of a specific agonist or antagonist at the target. Following incubation, the 
samples are filtered rapidly under vacuum through glass fiber filters 
presoaked in a buffer and rinsed several times with an ice-cold buffer 
using a 96-sample cell harvester. The filters are dried then counted for 
radioactivity in a scintillation counter using a scintillation cocktail. The 
results are expressed as a percent inhibition of the control radioligand 
specific binding.[40] 
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